TuHURA Biosciences Retained Earnings Over Time
| HURA Stock | 5.93 0.75 11.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out TuHURA Biosciences Performance and TuHURA Biosciences Correlation. TuHURA |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TuHURA Biosciences. If investors know TuHURA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TuHURA Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of TuHURA Biosciences is measured differently than its book value, which is the value of TuHURA that is recorded on the company's balance sheet. Investors also form their own opinion of TuHURA Biosciences' value that differs from its market value or its book value, called intrinsic value, which is TuHURA Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TuHURA Biosciences' market value can be influenced by many factors that don't directly affect TuHURA Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TuHURA Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if TuHURA Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TuHURA Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare TuHURA Biosciences and related stocks such as Dogwood Therapeutics,, Viking Therapeutics, and Vanda Pharmaceuticals Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DWTX | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (28 M) | (43.9 M) | (56.2 M) | (61.5 M) | (64.5 M) |
| VKTX | (111 K) | (111 K) | (111 K) | (257.3 K) | (22.1 M) | (45.5 M) | (60.3 M) | (80.9 M) | (102.9 M) | (128.7 M) | (168.2 M) | (223.2 M) | (292 M) | (377.9 M) | (359 M) |
| VNDA | (12.4 M) | (263.4 M) | (291.1 M) | (311.4 M) | (288 M) | (327.8 M) | (345.9 M) | (361.4 M) | (336.2 M) | (220.7 M) | (197.3 M) | (164.2 M) | (157.9 M) | (155.4 M) | (163.2 M) |
| VRCA | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.4 M) | (33.1 M) | (61.2 M) | (103.9 M) | (139 M) | (163.5 M) | (230.4 M) | (218.9 M) |
| VRDN | (21.4 M) | (21.4 M) | (21.4 M) | (25.9 M) | (6.6 M) | (18 M) | (30.6 M) | (93.6 M) | (126.3 M) | (168.2 M) | (278.9 M) | (358.3 M) | (488.2 M) | (725.9 M) | (689.6 M) |
| VRNA | 44.7 K | (12.7 M) | (17.2 M) | (21.7 M) | (24.5 M) | (34.2 M) | (35.4 M) | (66.6 M) | (87.7 M) | (131.9 M) | (207.1 M) | (263.7 M) | (333.1 M) | (388.4 M) | (369 M) |
| VRPX | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (6.3 M) | (10.6 M) | (22.7 M) | (44.4 M) | (59.5 M) | (56.6 M) |
| VRTX | (6.2 M) | (3.4 B) | (3.5 B) | (4 B) | (4.7 B) | (5.3 B) | (5.4 B) | (5.1 B) | (3 B) | (1.9 B) | 858.7 M | 3.2 B | 6.5 B | 10.1 B | 10.6 B |
| VSTM | (14.5 M) | (14.5 M) | (46.5 M) | (87.7 M) | (141 M) | (198.9 M) | (235.3 M) | (303.1 M) | (375.6 M) | (524.8 M) | (592.5 M) | (663.7 M) | (737.5 M) | (824.9 M) | (783.6 M) |
| VTGN | (10.2 K) | (54.8 M) | (67.7 T) | (70.6 B) | (84.5 M) | (131.7 M) | (142 M) | (156.5 M) | (181.1 M) | (201.9 M) | (219.8 M) | (267.6 M) | (326.9 M) | (356.2 M) | (374 M) |
TuHURA Biosciences and related stocks such as Dogwood Therapeutics,, Viking Therapeutics, and Vanda Pharmaceuticals Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| TuHURA Biosciences | HURA |
Specialization | Healthcare, Biotechnology |
| Exchange | NASDAQ Exchange |
null 5.93
Check out TuHURA Biosciences Performance and TuHURA Biosciences Correlation. For information on how to trade TuHURA Stock refer to our How to Trade TuHURA Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
TuHURA Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.